Insitro
Decodes biology using machine learning to discover new medicines
a16z — Backed by a16z
SoftBank Vision Fund — Backed by SoftBank Vision Fund H-1B sponsor history — This employer has had H-1B petitions approved by USCIS in the last five fiscal years, per the USCIS H-1B Employer Data Hub. The approval belongs to the employer and is not a commitment to sponsor this role.Company facts
- Founded
- 2018
- Employees
- 253
- Headquarters
- United States
- CEO
- Daphne Koller
- Type
- Private
- Funding
- Series C · $400M · 2021
- Subsidiaries
- CombinAble.AI
About
Insitro is a data-driven biotech company focused on transforming drug discovery through machine learning and high-throughput biology. By integrating human genetics, functional genomics, and advanced computational methods, the company aims to accelerate the development of new therapies at lower costs, addressing unmet medical needs more effectively. Insitro's unique approach leverages diverse expertise in life sciences, engineering, and data science, fostering a collaborative culture dedicated to improving patient health outcomes.
Open positions


Senior Director, Project & Portfolio Management
The Opportunity The unprecedented convergence of multi-modal data, advanced disease modeling, and computational power is revolutionizing drug discovery. insitro is harnessing this moment to redefine how medicines are…